Amneal Pharmaceuticals, Inc. AMRX Interest Income (Expense), Nonoperating
Interest Income (Expense), Nonoperating at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s interest income (expense), nonoperating?
- Amneal Pharmaceuticals, Inc. (AMRX) reported interest income (expense), nonoperating of -$53.36M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s interest income (expense), nonoperating changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s interest income (expense), nonoperating increased by 6.3% year-over-year, from -$56.94M to -$53.36M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s interest income (expense), nonoperating?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s interest income (expense), nonoperating has grown at a 15.3% compound annual growth rate (CAGR), from -$136.33M to -$241.09M.